Artificial Pancreas
Automated insulin delivery safe, effective for children aged 5 years and younger
CHICAGO — Children aged 5 years and younger with type 1 diabetes have similar reductions in HbA1c at 6 months with use of an automated insulin delivery system as children aged 6 to 10 years, researchers reported.
Hybrid closed-loop insulin therapy improves glycemic control in pregnant women with diabetes
CHICAGO — Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time in pregnancy range per day compared with women who followed standard care, trial results show.
Semaglutide benefits extend to type 1 diabetes
CHICAGO — Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia compared with placebo in patients with type 1 diabetes and obesity using an automated insulin delivery system.
‘New era’ of diabetes technology advancing care for wide range of patients
The evolution of diabetes technologies has led to the expansion of automated insulin delivery for type 2 diabetes, continuous glucose monitoring for people without diabetes and calls for a higher standard of care in type 1 diabetes.
Hybrid closed-loop system provides glycemic benefits, may be cost-effective in pregnancy
An advanced hybrid closed-loop insulin delivery system is safe to use for pregnant women with type 1 diabetes and may provide some glycemic benefits, especially during overnight hours, according to a presenter.
Automated insulin delivery may be ‘key first-line therapy’ for type 1 diabetes
Patients with type 1 diabetes initiating automated insulin delivery had a significantly lower HbA1c at 13 weeks than those receiving multiple daily insulin injections, according to a presenter.
Automated insulin delivery provides range of glycemic benefits in type 2 diabetes
Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of an automated insulin delivery system compared with standard care, according to findings from a new trial.
Q&A: How adults with type 1 diabetes can become commercial airline pilots
Data from the Barbara Davis Center for Diabetes at University of Colorado show pilots with type 1 diabetes are not just thriving in the air, but also with their diabetes management.
Automated insulin delivery lowers HbA1c, improves time in range in type 2 diabetes
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated insulin delivery system, according to findings from the SECURE-T2D trial.
Although superior to other insulin therapies, hybrid closed-loop systems differ in efficacy
Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in Diabetes/Metabolism Research and Reviews.